Five years of sequential LAM to LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma - Lampertico,P.; Vigano,P.; Manenti,E. (Hepatology, 2005)